The Manila Times

Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-drive…

Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on ...
Las Vegas Sun

Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology

Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, is leading an oversubscribed $75 million (€ 65 million 2 ) Series C financing round in Adcendo ApS ...
EurekAlert!

Development of 1-Wh-class stacked lithium-air cells

(A) Schematic illustration of the synthesis process for a carbon material with controlled mesoscale porosity. (B) External view of the 1-Wh-class stacked lithium-air battery fabricated in this study.

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head ...
Business Wire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...